We have read with great interest the article of Carreras et al., 1 in which the authors proposed to better characterize the clinical criteria for the diagnosis of engraftment syndrome (ES) , to analyze the suspected increasing incidence and to identify risk factors favoring this complication.
We report in this study our own single center experience with this clinically challenging and not yet fully understood and recognizable syndrome, due to the complexity of its differential diagnosis and overlapping features with other entities.
From January 2006 to June 2010, a total of 265 consecutive peripheral blood auto-hematopoietic stem cell transplants (auto-HSCT) (patient's median age 48 (range 17-69 years); male, 143/54% and female, 122/46%; underlying disease: multiple myeloma (MM), 124/47%; nonHodgkin lymphoma, 61/23%, Hodgkin lymphoma, 53/ 20% and other pathologies including acute myeloid leukemia and solid tumors (27/10%)) were performed in our center (Table 1) . PBPCs were obtained after mobilization with G-CSF ± chemotherapy. The median cellularity of CD34 þ cells/kg was 3. ). Conditioning regimens were high-dose melphalan (MM), BEAC (non-Hodgkin lymphoma and Hodgkin lymphoma). No anti-microbial prophylaxis was given except viral prophylaxis for herpes simplex (HSV) reactivation. G-CSF was given from day 7 after auto-HSCT. Median times to neutrophil (X0.5 Â 10 9 /L) and platelet (X20 Â 10 9 /L) engraftment were 11 and 14 days, respectively. Bacteriemia rate among the patients submitted to auto-HSCT was 21% (mainly Gram negative bacilli), and none of the patients with suspected ES had microbiological documentation.
Overall, 18 (7%) of 265 auto-HSCT, developed clinical and biological features suggestive of ES, half of them requiring corticotherapy. No fatal cases due to ES occurred. During the peri-engraftment period symptoms consisted of fever without microbiological documentation, 18/18 (100%) plus one or more of the following clinical signs: hepatic dysfunctions 13/18 (72%), skin rash, 10/18 (56%), diarrhea 2/18 (11%) and pulmonary infiltrates or edema (without hypoxemia) documented by 'X-ray' or computed tomography scan 2/18 (11%). No weight gain, renal dysfunction or transient encephalopathy developed in any of the patients suspected of having ES in our series. If considering the more stringent but less sensitive Spitzer criteria, 2 with symptoms occurring within 96 h of engraftment, only 8/265 (3%) had ES; using the Maiolino criteria (MC), 3 which accept the diagnosis of ES from 24 h before to any time after the appearance of the first neutrophils in peripheral blood, the incidence went up to 13/265 (5%), thus suggesting that MC diagnostic time frame allows the detection of more cases of possible ES. One important issue to mention is that besides those 13 patients that fulfilled Spitzer and/or Maiolino diagnostic criteria, we considered five additional patients as having a diagnosis of ES, thus giving a total incidence of 18/265 (7%). These five patients presented with fever of noninfectious origin plus hepatic dysfunction only (mainly elevated transaminases) without any other explicable reason, for example drug toxicity, infections, hepatic veno-occlusive disease according to Seattle or Baltimore criteria (no jaundice, hepatomegaly, right upper quadrant pain or weight gain) besides an ES and three of them required steroid therapy. Spitzer criteria include hepatic dysfunction (bilirubinX2 mg/100 mL or ALAT/ASATX2 times) as a minor criterion but those five cases do not fit the overall Spitzer criteria requirements. On the other hand MC did not include hepatic dysfunction. However, in their study they only analyzed jaundice (bilirubin) and not the ALAT/ASAT levels. Although the pathogenesis of ES is not well understood, the current concept involves the release of pro-inflammatory cytokines and other products of degranulation and oxidative metabolism upon neutrophil recovery, which could lead to endothelial damage and ultimately multiorgan failure including hepatocyte damage with elevation of transaminase levels. 2, 4 By not considering hepatic dysfunction, MC may ignore many situations of possible ES, like the five aforementioned cases, jeopardizing the final outcome. Thus, we suggest that hepatic dysfunction should be added to MC to increase their sensitivity, however, larger prospective studies are necessary to validate this.
Our data support the findings of Carreras et al. that C-reactive protein values are elevated and correlate well with ES cases, and could be a good aid to the diagnosis of ES in dubious cases (such as those five patients with only non-infectious fever and hepatic dysfunction). 1 In our ES series, all 18 patients had high C-reactive protein levels during engraftment period (median 15.9 mg/L; range 6.20-32.3 mg/L).
We also tried to analyze the risk factors for ES, but contrary to the other studies which suggested that female sex, dose of CD34 þ /kg, use of PBPC, conditioning regimen, use of G-CSF and rate of engraftment as risk factors for ES, in our study none were statistically significant. [5] [6] [7] It is noteworthy that one MM patient developed ES in both auto-HSCT that he received, the second time requiring steroid therapy. This observation raises two important questions: (1) does having ES in a previous transplant increase the risk of developing it again?; (2) if so, is steroid prophylaxis advisable in this case?
In our series, previous ES appears to be a risk factor for its reappearance in the next auto-HSCT (Fisher exact test Po0.02), an observation that has never been explored before in other studies. Unfortunately, although statistically significant, this is only one single case and we cannot draw any definitive conclusion. A larger cohort of patients is necessary to confirm our observation. On the other hand, steroid prophylaxis should be feasible in this situation as Mossad et al. 8 already proposed in their report that steroids prevent ES after auto-HSCT without increasing the risk of infection.
In summary, ES is a tricky diagnostic entity. Revision of the current diagnostic criteria is recommended to increase the sensitivity of its detection, as this is a syndrome that can evolve to the stage of multiorgan failure/death and is highly avoidable if a timely therapy is instituted. Its prompt recognition reduces drastically the use of unnecessary antimicrobial agents, toxicities, the time of hospitalization and ultimately the overall monetary costs.
